» Articles » PMID: 18445575

Trends in Antimicrobial Susceptibility of Gram-negative Isolates from a Paediatric Intensive Care Unit in Warsaw: Results from the MYSTIC Programme (1997-2007)

Overview
Date 2008 May 1
PMID 18445575
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme is a longitudinal global surveillance study to monitor in vitro data on microbial susceptibility in centres that prescribe meropenem. This overview provides data on the susceptibility of Gram-negative bacteria (n = 1300) isolated from clinical specimens of children hospitalized in a paediatric intensive care unit (ICU) during 1997-2007.

Methods: MICs of meropenem and eight other antibiotics were determined using the CLSI agar dilution method.

Results: Meropenem, imipenem and ciprofloxacin were most active (>90% susceptibility) against the tested isolates. A greater proportion of Pseudomonas aeruginosa isolates was susceptible to meropenem compared with imipenem. Antibiotic susceptibility of Enterobacteriaceae and Acinetobacter baumannii showed an increase in 2007. Only susceptibility of P. aeruginosa to ceftazidime and cefepime increased. The incidence of extended-spectrum beta-lactamase (ESBL) producers among Enterobacteriaceae isolates decreased from 37% in 1997 to 21.8% in 2007, and AmpC beta-lactamase producers decreased from 24.6% to 5.7%. Consumption of cephalosporins remained the same and piperacillin/tazobactam increased 3-fold. During 11 years, despite an increase in carbapenem consumption, meropenem and imipenem have retained excellent activity against the majority of isolates studied.

Conclusions: The comparison of antibiotic susceptibility of Gram-negative isolates in 1997 and 2007 showed a trend of increase, and the number of beta-lactamase-producing isolates among Enterobacteriaceae showed a trend of decrease possibly related to changes in antibiotic policy.

Citing Articles

Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.

Beig M, Parvizi E, Navidifar T, Bostanghadiri N, Mofid M, Golab N PLoS One. 2024; 19(12):e0311124.

PMID: 39680587 PMC: 11649148. DOI: 10.1371/journal.pone.0311124.


Occurrence and antimicrobial susceptibility of enteric rods and pseudomonads isolated from the dental prostheses biofilm.

Silva S, de Oliveira Ribeiro M, Fernandes Gomes F, Chaves H, Rodrigues E Silva A, Zanin I J Appl Oral Sci. 2016; 24(5):462-471.

PMID: 27812616 PMC: 5083023. DOI: 10.1590/1678-775720160032.


Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Roberts J, Abdul-Aziz M, Lipman J, Mouton J, Vinks A, Felton T Lancet Infect Dis. 2014; 14(6):498-509.

PMID: 24768475 PMC: 4181663. DOI: 10.1016/S1473-3099(14)70036-2.


Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.

Joly-Guillou M, Kempf M, Cavallo J, Chomarat M, Dubreuil L, Maugein J BMC Infect Dis. 2010; 10:72.

PMID: 20298555 PMC: 2845586. DOI: 10.1186/1471-2334-10-72.


Epidemiology of invasive neonatal Cronobacter (Enterobacter sakazakii) infections.

Friedemann M Eur J Clin Microbiol Infect Dis. 2009; 28(11):1297-304.

PMID: 19662446 DOI: 10.1007/s10096-009-0779-4.